VIRI
NASDAQVirios Therapeutics Inc.
Latest news
25 items- 13D/GSEC Form SC 13D filed by Virios Therapeutics Inc.SC 13D - Virios Therapeutics, Inc. (0001818844) (Subject)
- SECSEC Form DEFA14A filed by Virios Therapeutics Inc.DEFA14A - Virios Therapeutics, Inc. (0001818844) (Filer)
- SECVirios Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Virios Therapeutics, Inc. (0001818844) (Filer)
- PRVirios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: "DWTX")Strategic financing by an affiliate of CK Life Sciences Int'l., (Holdings) Inc., results in working capital of approximately $23 million to fund operations and advance Phase 2b Halneuron® development into 4Q25 Expanded pipeline includes a potential first-in-class non-opioid, NaV1.7 inhibition pain treatment, Halneuron®, currently in Phase 2b development for chemotherapy-induced neuropathic pain, with an expected interim readout 2H25Near-term catalyst with top-line results from the IMC-2 Long-COVID Phase 2a study expected in early 4Q24 Existing VIRI stockholders to be granted a contingent value right ("CVR") tied to potential milestone payments associated with any future corporate partneri
- SECSEC Form 10-Q filed by Virios Therapeutics Inc.10-Q - Virios Therapeutics, Inc. (0001818844) (Filer)
- SECVirios Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Virios Therapeutics, Inc. (0001818844) (Filer)
- PRVirios Therapeutics Announces Second Quarter 2024 Financial Results- Bateman Horne Center completed enrollment in its groundbreaking investigator-initiated Long-COVID phase 2a study featuring valacyclovir and celecoxib (IMC-2) - - Top-line results from the Bateman Horne Center's Long-COVID phase 2a study expected in October 2024, will provide key insights into final design of planned Phase 2b study - ATLANTA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID ("LC"), today announced financial results for the second quarter ended June 30, 2
- PRVirios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024ATLANTA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID ("LC"), announced today that it will report second quarter 2024 financial results on Thursday, August 8, 2024 before the open of the financial markets. About Virios Therapeutics Virios Therapeutics (NASDAQ:VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia ("FM") and Long-CO
- NEWSVirios Therapeutics shares are trading higher after the company announced the Bateman Horne Center completed enrollment in its investigator-initiated, proof of concept LC study.
- NEWSVirios Therapeutics Announces Completion Of Enrollment In Proof Of Concept Long-COVID Study; Top Line Results Expected In October 2024; Study Highlights Potential For Antiviral Therapy To Treat Long-COVID Symptoms
- PRVirios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center- Virios projects releasing top line results from this groundbreaking Proof of Concept study in October 2024 - - Published data indicates increased Epstein-Barr herpes virus in Long-COVID patients, highlighting potential for antiviral therapy to treat fatigue and other Long-COVID symptoms - ATLANTA, July 23, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID ("LC"), today announced that the Bateman Horne Center ("BHC") has completed enrollment in its investigator-initiated, proof of con
- NEWSWhy CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday's Mid-Day SessionShares of CrowdStrike Holdings, Inc. (NASDAQ:CRWD) fell sharply during Monday’s session. Guggenheim analyst John Difucci downgraded the stock from Buy to Neutral, while BTIG analyst Gray Powell downgraded the stock from Buy to Neutral. CrowdStrike shares dipped over 11% on Friday after the company suffered a major outage impacting businesses around the world. Selective Insurance Group shares dipped 13.2% to $264.65 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) shares climbed 148% to $1.98 after the company announced new preclinical study results for its novel oral ketamine analog, Ketamir-2. CareMa
- NEWSWhy Tellurian Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving PremarketShares of Tellurian Inc. (NASDAQ:TELL) rose sharply in today's pre-market trading after Woodside Energy announced plans to acquire the company for $900 million in all-cash deal. The implied enterprise value is around $1,200 million. Tellurian shares jumped 65% to $0.9422 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Netcapital Inc. (NASDAQ:NCPL) rose 43.8% to $0.1495 in pre-market trading after jumping more than 12% on Friday. Netcapital, last week, announced the launch of the beta version of its secondary trading platform. Serve Robotics Inc. (NASDAQ:SERV) gained 36.8% to $10.33 in pre-market trading. Serve Robotics shares jumped
- NEWSWhy Chuy's Holdings Shares Are Trading Higher By 47%; Here Are 20 Stocks Moving PremarketShares of Chuy’s Holdings, Inc. (NASDAQ:CHUY) rose sharply in today's pre-market trading after the company and Darden Restaurants, Inc. (NYSE:DRI) jointly announced that Darden will acquire Chuy's Holdings. Chuy's Holdings and Darden entered into a definitive agreement in which Darden will acquire all of Chuy's outstanding stock for $37.50 per share in cash. The all-cash transaction has an enterprise value of approximately $605 million. Chuy’s Holdings shares jumped 47.4% to $37.27 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Onconetix, Inc. (NASDAQ:ONCO) gained 65% to $0.2458 in pre-market trading. On July 15, Onconetix announced cl
- SECVirios Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Virios Therapeutics, Inc. (0001818844) (Filer)
- NEWSWhy Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving PremarketShares of Vuzix Corporation (NASDAQ:VUZI) rose sharply in today's pre-market trading after the company disclosed a strategic partnership with Avegant to develop optimized waveguide optical modules for use in future AI-enabled smart glasses. Vuzix shares jumped 15% to $1.53 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers SMX (Security Matters) Public Limited Company (NASDAQ:SMX) rose 109.8% to $0.2497 in pre-market trading after jumping 19% on Tuesday. Selina Hospitality PLC (NASDAQ:SLNA) gained 46.9% to $0.1024 in pre-market trading after declining 7% on Tuesday. Tempest Therapeutics, Inc. (NASDAQ:TPST) shares rose 44.5%
- NEWSMaxim Group Initiates Coverage On Virios Therapeutics with Buy Rating, Announces Price Target of $1Maxim Group analyst Jason McCarthy initiates coverage on Virios Therapeutics (NASDAQ:VIRI) with a Buy rating and announces Price Target of $1.
- SECVirios Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Virios Therapeutics, Inc. (0001818844) (Filer)
- NEWSWhy G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionShares of G-III Apparel Group, Ltd. (NASDAQ:GIII) fell sharply during Thursday's session after the company reported worse-than-expected quarterly sales results. G-III Apparel Group posted adjusted earnings of 13 cents per share, according to data from Benzinga Pro. The company's quarterly sales came in at $609.747 million, missing market estimates of $616.286 million. G-III Apparel Group shares dipped 13.4% to $27.12 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Virax Biolabs Group Limited (NASDAQ:VRAX) shares jumped 139.4% to $2.5390. American Oncology Network, Inc. (NASDAQ:AONC) gained 102% to $4.52. American Oncology Network expanded
- NEWS12 Health Care Stocks Moving In Thursday's After-Market SessionGainers MyMD Pharmaceuticals (NASDAQ:MYMD) stock rose 46.0% to $2.89 during Thursday's after-market session. The market value of their outstanding shares is at $6.6 million. Adaptimmune Therapeutics (NASDAQ:ADAP) stock moved upwards by 31.68% to $1.33. The market value of their outstanding shares is at $339.8 million. China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) shares moved upwards by 12.83% to $0.33. BiomX (AMEX:PHGE) stock rose 6.24% to $0.44. The market value of their outstanding shares is at $31.0 million. Virios Therapeutics (NASDAQ:VIRI) stock increased by 6.12% to $0.22. The market value of their outstanding shares is at $6.1 million. Accuray (NASDAQ:ARAY) stock increas
- NEWS12 Health Care Stocks Moving In Tuesday's After-Market SessionGainers Reshape Lifesciences (NASDAQ:RSLS) shares rose 88.9% to $0.39 during Tuesday's after-market session. The market value of their outstanding shares is at $9.2 million. Dermata Therapeutics (NASDAQ:DRMA) stock rose 12.8% to $3.7. The company's market cap stands at $1.6 million. Shuttle Pharmaceuticals (NASDAQ:SHPH) stock moved upwards by 7.88% to $0.47. The company's market cap stands at $7.8 million. Ocular Therapeutix (NASDAQ:OCUL) shares rose 7.25% to $6.36. The market value of their outstanding shares is at $985.0 million. Unicycive Therapeutics (NASDAQ:UNCY) shares rose 6.02% to $0.89. The company's market cap stands at $33.4 million. Virios Therapeutics (NASDAQ:VIRI) shares
- PRVirios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyATLANTA, May 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company" or "Virios Therapeutics"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID ("LC"), today announced the closing of its previously announced public offering of 8,500,000 shares of its common stock at a public offering price of $0.20 per share. Gross proceeds from the offering are $1.7 million before deducting placement agent fees and offering expenses. Virios Therapeutics intends to use the net proceeds of the offering to commence preparatory activities for its planned IMC
- NEWSVirios Therapeutics Inc. To Offer 8.5M Shares Of Common Stock At $0.20 Per Share- SEC Filing
- SECSEC Form 424B4 filed by Virios Therapeutics Inc.424B4 - Virios Therapeutics, Inc. (0001818844) (Filer)
- NEWSDow Falls Over 150 Points; Sohu Posts Q1 LossU.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 150 points on Monday. The Dow traded down 0.43% to 39,831.18 while the NASDAQ rose 0.53% to 16,775.01. The S&P 500 also rose, gaining, 0.09% to 5,307.88. Check This Out: Top 3 Financial Stocks That Are Set To Fly This Quarter Leading and Lagging SectorsInformation technology shares rose by 1.3% on Monday. In trading on Monday, financial shares fell by 0.7%. Top Headline Shares of Sohu.com Limited (NASDAQ:SOHU) edged higher on Monday after the company reported its results for the fiscal first quarter of 2024. Sohu.com reported a revenue decline of 14% year-over-year to $139.4 m
VIRI FAQ
7 questionsWhat does Virios Therapeutics Inc. do?
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Its lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was incorporated in 2012 and is headquartered in Alpharetta, Georgia.Where does VIRI stock trade?
Virios Therapeutics Inc. (VIRI) is listed on NASDAQ.What sector and industry is VIRI in?
Virios Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Virios Therapeutics Inc. go public?
Virios Therapeutics Inc. (VIRI) completed its IPO in 2020.What are analysts saying about VIRI?
Virios Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from HC Wainwright & Co.: Buy with a $1200.00 price target on 2021-12-15. Recent price targets cluster around $1200.00.What companies are similar to VIRI?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare VIRI side-by-side with any of them on Quantisnow.How can I track VIRI on Quantisnow?
Quantisnow aggregates Virios Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VIRI to receive live email and push alerts on every new disclosure.